B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC22A2

MOLECULAR TARGET

solute carrier family 22 member 2

UniProt: Q9R0W2NCBI Gene: 2950317 compounds

SLC22A2 (solute carrier family 22 member 2) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC22A2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Corticosterone1.956
2Cimetidine1.614
3Ondansetron1.102
4Progesterone0.691
5Carvedilol0.691
6Chlorhexidine0.691
7Desoxycorticosterone0.691
8Dinoprost0.691
9Dinoprostone0.691
10Dolutegravir0.691
11Domperidone0.691
12Ethinyl Estradiol0.691
13Gabexate0.691
14Irinotecan0.691
15Noscapine0.691
16pentamidine0.691
17Vecuronium Bromide Monoquaternary homolog of PANCURONIUM.0.691

About SLC22A2 as a Drug Target

SLC22A2 (solute carrier family 22 member 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented SLC22A2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC22A2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.